Gouty Arthritis (Gout) - Pipeline Review, H1 2020

May 2020 | 125 pages | ID: GE54ED2AA63EN
Global Markets Direct

Abstracts

Gouty Arthritis (Gout) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gouty Arthritis – Pipeline Review, H1 2020, provides an overview of the Gouty Arthritis (Musculoskeletal Disorders) pipeline landscape.

Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area and joint redness. Risk factors include obesity, high alcohol intake, injury to a joint, long-standing kidney disease and high intake of foods rich in purines.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gouty Arthritis – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Gouty Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gouty Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 2, 15, 6, 1, 20 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Gouty Arthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Musculoskeletal Disorders).
• The pipeline guide reviews pipeline therapeutics for Gouty Arthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Gouty Arthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Gouty Arthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Gouty Arthritis (Musculoskeletal Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Gouty Arthritis (Musculoskeletal Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Gouty Arthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Gouty Arthritis (Gout) - Overview
Gouty Arthritis (Gout) - Therapeutics Development
Gouty Arthritis (Gout) - Therapeutics Assessment
Gouty Arthritis (Gout) - Companies Involved in Therapeutics Development
Gouty Arthritis (Gout) - Drug Profiles
Gouty Arthritis (Gout) - Dormant Projects
Gouty Arthritis (Gout) - Discontinued Products
Gouty Arthritis (Gout) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Gouty Arthritis (Gout), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Gouty Arthritis (Gout) - Pipeline by Acquist Therapeutics, H1 2020
Gouty Arthritis (Gout) - Pipeline by Aequus BioPharma Inc, H1 2020
Gouty Arthritis (Gout) - Pipeline by Arthrosi Therapeutics Inc, H1 2020
Gouty Arthritis (Gout) - Pipeline by C&C Research Laboratories, H1 2020
Gouty Arthritis (Gout) - Dormant Projects, H1 2020
Gouty Arthritis (Gout) - Dormant Projects, H1 2020 (Contd..1), H1 2020
Gouty Arthritis (Gout) - Dormant Projects, H1 2020 (Contd..2), H1 2020
Gouty Arthritis (Gout) - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Gouty Arthritis (Gout), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Acquist Therapeutics
Aequus BioPharma Inc
Arthrosi Therapeutics Inc
C&C Research Laboratories
DevaCell Inc
Dyve Biosciences
Enzychem Lifesciences Corp
Fochon Pharmaceutical Ltd
FortuneRock (China) Ltd
Genentech Inc
General Genomics Llc
General Regeneratives Shanghai Ltd
GeneScience Pharmaceuticals Co Ltd
Hinova Pharmaceuticals Inc
Horizon Therapeutics Plc
InflammatoRx inc
InventisBio Inc
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
LG Chem Ltd
Novartis AG
Olatec Therapeutics LLC
Opsona Therapeutics Ltd
PegBio Co Ltd
Polaris Pharmaceuticals Inc
Protalix BioTherapeutics Inc
R Pharm
Rigel Pharmaceuticals Inc
Shanghai Yingli Pharmaceutical Co Ltd
Shanton Pharma Co Ltd
Swedish Orphan Biovitrum AB
TaiwanJ Pharmaceuticals Co Ltd
Teijin Pharma Ltd
TWi Biotechnology Inc
Wellstat Therapeutics Corp
XL-protein GmbH